Hematological Neoplasia

  • Ralph Waesch
  • Werner Digel
  • Michael Luebbert
  • Kristina Heining-Mikesch
  • Cornelius Waller
  • W. Lange
  • Jürgen Heinz
  • Jürgen Finke
  • Jan Burger
  • Gerald Illerhaus
  • Reinhard Marks
  • Alexandros Spyridonidis
  • Claudia I. Müller
  • Monika Engelhardt
  • Marcus Stockschläder


Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Mantle Cell Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukemia. Br J Hematol 2004;125:421–34Google Scholar
  2. 2.
    Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005;23:6306–15PubMedGoogle Scholar
  3. 3.
    Castor A, Nilsson L, Astrand-Grundstroem I et al. Distinct patterns of stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005;11:630–7PubMedGoogle Scholar
  4. 4.
    Hallbook H, Hagglund H, Stockelberg D et al. Autologous and allogeneic stem cell transplantation in adult ALL. Bone Marrow Transpl 2005;35:1141–8Google Scholar
  5. 5.
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Eng J Med 2006;354:166–78Google Scholar
  6. 6.
    Ravandi F. Role of cytokines in the treatment of acute leukemias. Leukemia 2006;20:563–71PubMedGoogle Scholar
  7. 7.
    Rowe JM, Goldstone AH. How I treat acute lymphocytic leukemia in adults. Blood 2007;110:2268–75PubMedGoogle Scholar
  8. 8.
    Szczepanski T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia. Leukemia 2007;21:622–6PubMedGoogle Scholar
  9. 1. Natl Cancer InstituteGoogle Scholar
  10. 2. Medline PlusGoogle Scholar
  11. 3. Leuk Lymph SocGoogle Scholar
  12. 4. EmedicineGoogle Scholar
  13. 5. Eur Leukemia NetworkGoogle Scholar
  14. 6. Atlas of LeukemiaGoogle Scholar
  15. 1.
    Bullinger L, Valk PJM. Gene-expression profiling in acute myeloid leukemia. J Clin Oncol 2005;23:6296–305PubMedGoogle Scholar
  16. 2.
    Craddock C, Tauro S, Moss P et al. Biology and management of relapsed acute myeloid leukemia. Br J Hematol 2005;129:18–34Google Scholar
  17. 3.
    Drobyski WR. The role of allogeneic transplantation in high-risk acute myelogenous leukemia. Leukemia 2004;18:1565–8PubMedGoogle Scholar
  18. 4.
    Estey H, Döhner H. Acute myeloid leukemia. Lancet 2006;368:1894–907.PubMedGoogle Scholar
  19. 5.
    Fey MF, ESMO Guidelines Task Force. Acute myeloblastic leukemia in adult patients: ESMO Clinical Recommendations for diagnosis, treatment and follow up. Ann Oncol 2007;18(suppl2):ii47–89PubMedGoogle Scholar
  20. 6.
    Milligan DW, Grimwade D, Cullis JO et al. British Committee for Standards in Haematology. Guidelines on the management of acute myeloid leukemia in adults. Br J Haematol 2006;135:450–74PubMedGoogle Scholar
  21. 7.
    Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002;14:24–30PubMedGoogle Scholar
  22. 8.
    Tallmann MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154–63Google Scholar
  23. 9.
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–302PubMedGoogle Scholar
  24. 1. Leukemia Lymphoma SocGoogle Scholar
  25. 2. Natl Marrow Donor ProgGoogle Scholar
  26. 3. Medline Plus, AMLGoogle Scholar
  27. 4. NCI PDQ, AMLGoogle Scholar
  28. 5. E-medicine, AMLGoogle Scholar
  29. 6. Eur Leukemia NetworkGoogle Scholar
  30. 1.
    Aul C, Giagounidis A, Germing U et al. A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81:485–97PubMedGoogle Scholar
  31. 2.
    Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Hematol 2003;120:187–200Google Scholar
  32. 3.
    Corey SJ, Minden MD, Barber DL et al. MDS: the complexity of stem-cell diseases. Nat Rev Cancer 2007;7:118–29PubMedGoogle Scholar
  33. 4.
    Golshayan AR, Jin T, Maciejewski J et al. Efficacy of growth factors compared to other therapies for low-risk MDS. Br J Haematol 2007,137:125–32PubMedGoogle Scholar
  34. 5.
    Howe RB, Porwit-MacDonald A, Wanat R et al. The WHO classification of MDS does make a difference. Blood 2004;103:3265–70PubMedGoogle Scholar
  35. 6.
    Luger S, Sacks N. Bone marrow transplantation for myelodysplastic syndrome: who? when? and which? Bone Marrow Transpl 2002;30:199–206Google Scholar
  36. 7.
    Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in MDS. J Clin Oncol 2007;25:3503–10PubMedGoogle Scholar
  37. 8.
    Olney HJ, LeBeau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of MDS. Leukemia Res 2007;31:427–34Google Scholar
  38. 9.
    Valent P, Horny HP, Bennet JM et al. Definitions and standards in the diagnosis and treatment of MDS: Consensus statements and report from a working conference. Leukemia Res 2007;31:727–36Google Scholar
  39. 1. Cancernet, NCIGoogle Scholar
  40. 2. NCI PDQGoogle Scholar
  41. 3. MDS FoundationGoogle Scholar
  42. 4. E-medicine, MDSGoogle Scholar
  43. 5.
    Campell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452–66Google Scholar
  44. 1.
    James C, Ugo V, LeCouedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–48PubMedGoogle Scholar
  45. 2.
    Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005;105:4187–90PubMedGoogle Scholar
  46. 3.
    Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–90PubMedGoogle Scholar
  47. 4.
    Michiels JJ, De Raeve H, Hebeda K et al. WHO bone marrow features and European clinical, molecular and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leukemia Res 2007;31:1031–8Google Scholar
  48. 5.
    Spivak JL, Barosi G, Tognoni G et al. Chronic myeloproliferative disorders. Hematology (ASH Educ Program) 2003:200–24Google Scholar
  49. 1. NCI PDQGoogle Scholar
  50. 2. Leuk lymph SocGoogle Scholar
  51. 3. MPD InformationGoogle Scholar
  52. 4. E-medicineGoogle Scholar
  53. 5. PathologyGoogle Scholar
  54. 1.
    Baccarani M, Sglio G, Goldman J et al. Evolving concepts in the management of CML: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809–20PubMedGoogle Scholar
  55. 2.
    Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010–22PubMedGoogle Scholar
  56. 3.
    Cortes C, Kantarjian HM. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 2005;23:6316–24PubMedGoogle Scholar
  57. 4.
    Goldman J. How I treat CML in the imatinib era. Blood 2007;110:2828–37PubMedGoogle Scholar
  58. 5.
    Hehlmann R, Hochhaus A, Baccarani M et al. Chronic myeloid leukemia. Lancet 2007;370:342–50PubMedGoogle Scholar
  59. 6.
    Melo JV, Barnes DJ. CML as a model of a disease evolution in human cancer. Nat Rev Cancer 2007;7:441–53PubMedGoogle Scholar
  60. 7.
    Schiffer CA. BCR-ABL tyrosine kinase inhibitors for CML. N Engl J Med 2007;357:258–65PubMedGoogle Scholar
  61. 8.
    Simonsson B, ESMO Guidelines Working Group. CML: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl.2)ii61–2Google Scholar
  62. 9.
    Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 2005;5:172–83PubMedGoogle Scholar
  63. 1. E-medicine, CMLGoogle Scholar
  64. 2. Leukemia Lymphoma SocGoogle Scholar
  65. 3. MedlinePlus CMLGoogle Scholar
  66. 4.
    Elliott MA, Tefferi A. Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Hematol 2004;128:275–90Google Scholar
  67. 5.
    Finazzi G, Caruso V, Marchioli R et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664–70PubMedGoogle Scholar
  68. 6.
    James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005;434:1144–8PubMedGoogle Scholar
  69. 7.
    Landolfi R, Marchioli R, Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–24PubMedGoogle Scholar
  70. 8.
    Levine L, Pardanani A, Tefferi A et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673–83.PubMedGoogle Scholar
  71. 9.
    McMullin MF, Bareford D, Campbell P et al. Guidelines for the diagnosis, investigation and management of polycythemia / erythrocytosis. Br J Hematol 2005;130:174–95Google Scholar
  72. 10.
    Schrader Al. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006;107:4214–22.Google Scholar
  73. 11.
    Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–7.PubMedGoogle Scholar
  74. 1. E-medicineGoogle Scholar
  75. 2. MPD-NetGoogle Scholar
  76. 3. Medline PlusGoogle Scholar
  77. 4. Am Acad Family PhysiciansGoogle Scholar
  78. 5. MPD InformationGoogle Scholar
  79. 1.
    Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. ASH Educational Program Book 2005:201–8Google Scholar
  80. 2.
    Chim CS, Kwong YL, Lie AK et al. Long-term outcome of 231 patients with essential thrombocythemia. Arch Intern Med 2005;165:2651–8PubMedGoogle Scholar
  81. 3.
    Finazzi G, Harrison CN. Essential thrombocythemia. Semin Hematol 2005;42:230–8PubMedGoogle Scholar
  82. 4.
    Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130:153–65PubMedGoogle Scholar
  83. 5.
    Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33–45PubMedGoogle Scholar
  84. 6.
    Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211–9PubMedGoogle Scholar
  85. 7.
    Steurer M, Gastl G, Jedrzejczak WW et al. Anagrelide for thrombocytosis in myeloproliferative disorders. Cancer 2004;101:2239–46PubMedGoogle Scholar
  86. 8.
    Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–7PubMedGoogle Scholar
  87. 1. E-medicineGoogle Scholar
  88. 2. pathology/Krause/ET/ET.html Tulane UniversityGoogle Scholar
  89. 3. Medline PlusGoogle Scholar
  90. 4. NCL Cancer TopicsGoogle Scholar
  91. 1.
    Arana-Yi C, Quintas-Cardama A, Giles F et al. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006;11:929–43PubMedGoogle Scholar
  92. 2.
    Barosi G, Bergamaschi G, Marchetti M et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030–6PubMedGoogle Scholar
  93. 3.
    Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005;128:585–92Google Scholar
  94. 4.
    Ciurea SO, Merchant D, Mahmud N et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007;110:986–993PubMedGoogle Scholar
  95. 5.
    Henessy BT, Thomas DA, Giles FJ et al. New approaches in the treatment of myelofibrosis. Cancer 2005;103:32–43Google Scholar
  96. 6.
    Papageorgiou SG, Castleton A, Bloor A et al. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006;38:721–7PubMedGoogle Scholar
  97. 7.
    Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092–7PubMedGoogle Scholar
  98. 8. Myelofibrosis NetworkGoogle Scholar
  99. 9. PMF, Medline PlusGoogle Scholar
  100. 10. E-medicineGoogle Scholar
  101. 1.
    Bonadonna G, Viviani S, Bonafante V et al. Survival in Hodgkin’s lymphoma. Eur J Cancer 2005;41:998–1006PubMedGoogle Scholar
  102. 2.
    Connors JM. State-of-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 2005;23:6400–8PubMedGoogle Scholar
  103. 3.
    Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann Oncol 2007;18(Suppl. 9):ix71–9PubMedGoogle Scholar
  104. 4.
    Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved field radiation in early stage Hodgkin’s disease. N Engl J Med 2007;357:1916–27PubMedGoogle Scholar
  105. 5.
    Jost L, ESMO Guidelines Working Group. Hodkin’s disease: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii53–4PubMedGoogle Scholar
  106. 6.
    Lavoien JC, Connors JM, Phillips GL et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Blood 2005;106:1473–8Google Scholar
  107. 7.
    Peggs KS, Hunter A, Chopra R et al. Clinical evidence of graft-versus-Hodgkin’s lymphoma effect after reduced-intensity allogenic transplantation. Lancet 2005;365:1934–41PubMedGoogle Scholar
  108. 8.
    Re D, Küppers R, Diehl V. Molecular pathogenesis of Hodgkin’s lymphoma. J Clin Oncol 2005;23:6379–86PubMedGoogle Scholar
  109. 9.
    Yung L, Linch D. Hodgkin’s lymphoma. Lancet 2003;361:943–51PubMedGoogle Scholar
  110. 1. NCI Cancer TopicsGoogle Scholar
  111. 2. E-medicineGoogle Scholar
  112. 3. Lymphoma Information NetworkGoogle Scholar
  113. 4. Medline PlusGoogle Scholar
  114. 5. Cancer BACKUPGoogle Scholar
  115. 1.
    Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368–76PubMedGoogle Scholar
  116. 2.
    Cheson BD, Pfister B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86PubMedGoogle Scholar
  117. 3.
    Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139–46PubMedGoogle Scholar
  118. 4.
    Fisher SG, Fisher RI. The epidemiology of non-Hodgkin’s lymphoma. Oncogene 2004;23:6524–34PubMedGoogle Scholar
  119. 5.
    Jaffe ES, Harris NL, Stein H et al. (eds) Pathology and Genetics of Tumors of the Hematopoietic and Lymphoid Tissues. WHO classification of tumors, IARC Press, Lyon, 2001Google Scholar
  120. 6.
    Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251–62PubMedGoogle Scholar
  121. 7.
    Kwee TC, Kwee RM, Nievelstein RAJ. Imaging in staging of malignant lymphoma. Blood 2008;111:504–16PubMedGoogle Scholar
  122. 8.
    Pals ST, De Gorter DJJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 2007;110:3102–11.PubMedGoogle Scholar
  123. 9.
    Rizvi MA, Evens, AM, Tallman MS et al. T-cell non-Hodgkin lymphoma. Blood 2006; 107:1255–64PubMedGoogle Scholar
  124. 1. Lymphoma Information NetworkGoogle Scholar
  125. 2. Leukemia Lymphoma SocietyGoogle Scholar
  126. 3.
non-hodgkins-lymphoma NCI Cancer TopicsGoogle Scholar
  127. 4. MedlinePlusGoogle Scholar
  128. 5.
Lymphomanon-Hodgkins Cancer BACKUPGoogle Scholar
  129. 6. E-medicineGoogle Scholar
  130. 7. Lymphoma Res FoundationGoogle Scholar
  131. 1.
    Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164–74PubMedGoogle Scholar
  132. 2.
    Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood 2007;110:29–36PubMedGoogle Scholar
  133. 3.
    Coiffier B, Lepage E, Brière J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42PubMedGoogle Scholar
  134. 4.
    ESMO Guidelines Task Force. Relapsed large B-cell non-Hodgkin’ lymphoma. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii55–6Google Scholar
  135. 5.
    ESMO Guidelines Task Force. Newly diagnosed large B-cell non-Hodgkin’s lymphoma. ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii57–8 Google Scholar
  136. 6.
    Ferry JA. Burkitt’s lymphoma. Oncologist 2006;11:375–83PubMedGoogle Scholar
  137. 7.
    Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–95PubMedGoogle Scholar
  138. 8.
    Pfreundschuh M, Trümper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626–33PubMedGoogle Scholar
  139. 9.
    Seropian S, Bahceci E, Cooper DL. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin’s lymphoma. Bone Marrow Transpl 2003;32:763–9Google Scholar
  140. 1. Lymphoma Info NetworkGoogle Scholar
  141. 2. E-medicineGoogle Scholar
  142. 3.
non-hodgkins-lymphoma NCI, Cancer TopicsGoogle Scholar
  143. 4. Lymphoma Info PortalGoogle Scholar
  144. 1.
    Abbott BL. Chronic lymphocytic leukemia. Oncologist 2006;11:21–30PubMedGoogle Scholar
  145. 2.
    Auer RL, Gribben J, Cotter FE. Emerging therapy for chronic lymphocytic leukaemia. Brit J Haematol 2007;139:635–44.Google Scholar
  146. 3.
    Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia. Lancet 2007;370:230–9PubMedGoogle Scholar
  147. 4.
    Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–15PubMedGoogle Scholar
  148. 5.
    ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii49–50Google Scholar
  149. 6.
    Montserrat E, Moreno C, Esteve J et al. How I treat refractory CLL. Blood 2006; 107:1276–83PubMedGoogle Scholar
  150. 7.
    Linet MS, Schubauer-Berigan MK, Weisenburger DD et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Brit J Haematol 2007;139:672–86.Google Scholar
  151. 8.
    Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005;23:6325–32PubMedGoogle Scholar
  152. 1.
CLL/HealthProfessional NCI, Cancer TopicsGoogle Scholar
  153. 2. CLL Links and InformationGoogle Scholar
  154. 3.
article/000532.htm MedlinePlusGoogle Scholar
  155. 4. E-medicineGoogle Scholar
  156. 5. CLL Research ConsortiumGoogle Scholar
  157. 1.
    Absi H, Hsi E, Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 2005;6:197–208PubMedGoogle Scholar
  158. 2.
    Cao TM, Coutre SE. T-cell prolymphocytic leukemia: update and focus on alemtuzumab. Hematology 2003;8:1–6PubMedGoogle Scholar
  159. 3.
    Castagna L, Nozza A, Bertuzzi A et al. Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in primary refractory prolymphocytic leukemia. Bone Marrow Transplant 2001;28:1155–66PubMedGoogle Scholar
  160. 4.
    Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721–6PubMedGoogle Scholar
  161. 5.
    McCune SL, Gockerman JP, Moore JO et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002;43:1007–11PubMedGoogle Scholar
  162. 6.
    Montillo M, Tedeschi A, O’Brien S et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003;97:114–20PubMedGoogle Scholar
  163. 7.
    Shvidel L, Shtalrid M, Bassous L et al. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 1999;33:169–79PubMedGoogle Scholar
  164. 8.
    Valbuena JR, Herling M, Admirand JH et al. T-cell prolymphocytic leukemia involving extramedullary sites. Am J Clin Pathol 2005;123:456–64PubMedGoogle Scholar
  165. 1. Leukemia Lymphoma SocietyGoogle Scholar
  166. 1.
    Else M, Ruchlemer R, Osuji N et al. Long remissions in hairy cell leukemia with purine analogues. Cancer 2005;104:2442–8PubMedGoogle Scholar
  167. 2.
    Falini B, Tiacci E, Liso A et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869–71PubMedGoogle Scholar
  168. 3.
    Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258–66PubMedGoogle Scholar
  169. 4.
    Jehn U, Bartl R, Dietzfelbinger H et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–81PubMedGoogle Scholar
  170. 5.
    Tiacci E, Liso A, Piris M et al. Evolving concepts in the pathogenensis of hairy-cell leukemia. Nat Rev Cancer 2006; 6:437–48PubMedGoogle Scholar
  171. 6.
    Wanko SO, De Castro C. Hairy cell leukemia. Oncologist 2006;11:780–9PubMedGoogle Scholar
  172. 1. E-medicineGoogle Scholar
  173. 2. Leukemia Lymphoma SocGoogle Scholar
  174. 3. Cancer TopicsGoogle Scholar
  175. 4. MedlinePlusGoogle Scholar
  176. 5. HCL Res FoundationGoogle Scholar
  177. 1.
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2005;22:1454–9Google Scholar
  178. 2.
    Bende RJ, Smit LA, Van Noessel CJM. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.PubMedGoogle Scholar
  179. 3.
    Brown J, Feng Y, Gribben JG. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transpl 2007;12:1057–65.Google Scholar
  180. 4.
    ESMO Guidelines Working Group. Newly diagnosed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;18(Suppl.2):ii63–4Google Scholar
  181. 5.
    Hiddemann W, Buske C, Dreyling M et al. Current management of follicular lymphomas. Br J Haematol 2006;136:191–202PubMedGoogle Scholar
  182. 6.
    Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441–9PubMedGoogle Scholar
  183. 7.
    Solal-Celigny P, Roy P, Colombat P et al. Follicular Lymphoma International Prognostic Index. Blood 2004;104:1258–65PubMedGoogle Scholar
  184. 8.
    Staudt LM. A closer look at follicular lymphoma. N Engl J Med 2007;356;741–2.PubMedGoogle Scholar
  185. 1. Lymphoma Info NetworkGoogle Scholar
  186. 2. E-medicineGoogle Scholar
  187. 3. Lymphoma Info PortalGoogle Scholar
  188. 4. Leukemia Lymphoma SocGoogle Scholar
  189. 5.
adult-non-hodgkins/healthprofessional NCI, Cancer TopicsGoogle Scholar
  190. 1.
    Bertoni F, Zucca E, Cavalli F. Mantle cell lymphoma. Curr Opin Hematol 2004;11:411–8PubMedGoogle Scholar
  191. 2.
    Fernàndez V, Hartmann E, Ott G et al. Pathogenesis of mantle cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005;23:6364–9PubMedGoogle Scholar
  192. 3.
    Hagemeister FB. Mantle cell lymphoma: non-myeloablative vs. dose-intensive therapy. Leuk Lymphoma 2003;44(suppl 3):S69–75PubMedGoogle Scholar
  193. 4.
    Kiss TL, Mollee P, Lazarus HM et al. Stem cell transplantation for mantle cell lymphoma: if, when and how? Bone Marrow Transplant 2005;36:655–61PubMedGoogle Scholar
  194. 5.
    Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004;83:71–7PubMedGoogle Scholar
  195. 6.
    Leonard JP, Schattner EJ, Coleman M. Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001;13:342–7PubMedGoogle Scholar
  196. 7.
    Witzig TE. Current treatment approaches for mantle cell lymphoma. J Clin Oncol 2005;23:6409–14PubMedGoogle Scholar
  197. 8.
    Zelenetz AD. Mantle cell lymphoma. Ann Oncol 2006;17(suppl 4):iv12–4PubMedGoogle Scholar
  198. 1. Lymphoma Info NetworkGoogle Scholar
  199. 2. E-medicineGoogle Scholar
  200. 3. Lymphoma Info PortalGoogle Scholar
  201. 4.
Lymphomanon-Hodgkins/TypesofNHL/Mantlecell Cancer BACKUPGoogle Scholar
  202. 5.
    ESMO Guidelines Working Group. Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii61–2Google Scholar
  203. 1.
    Foss F. Mycosis fungoides and the Sézary syndrome. Curr Opin Oncol 2004;16:421–8PubMedGoogle Scholar
  204. 2.
    Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350:1978–88PubMedGoogle Scholar
  205. 3.
    Hwang ST, Janik JE, Jaffe ES et al. Mycosis fungoides and Sézary syndrome. Lancet 2008;371:945–57.PubMedGoogle Scholar
  206. 4.
    Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the ISCL and the cutaneous lymphoma task force of the EORTC. Blood 2007;110:1713–22PubMedGoogle Scholar
  207. 5.
    Querfeld C, Rosen ST, Guitart J et al. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol 2005;12:273–8PubMedGoogle Scholar
  208. 6.
    Smith BD, Smith GL, Cooper DL et al. The cutaneous B-cell lymphoma prognostic index. J Clin Oncol 2005;23:3390–5PubMedGoogle Scholar
  209. 7.
    Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides / Sézary syndrome. Eur J Cancer 2006;42:1014–30PubMedGoogle Scholar
  210. 1. E-medicineGoogle Scholar
  211. 2.
mycosisfungoides/HealthProfessional NCI Cancer TopicsGoogle Scholar
  212. 3. Lymphoma Info NetworkGoogle Scholar
  213. 4. Cutaneous Lymph FoundationGoogle Scholar
  214. 5. Dermatology AtlasGoogle Scholar
  215. 1.
    Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–43PubMedGoogle Scholar
  216. 2.
    Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281–8PubMedGoogle Scholar
  217. 3.
    Bessell EM, Hoang-Xuan K, Ferreri AJM et al. Primary central nervous system lymphoma – Biological aspects and controversies in management. Eur J Cancer 2007;43:1141–52.PubMedGoogle Scholar
  218. 4.
    DeAngelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004;31:684–92PubMedGoogle Scholar
  219. 5.
    Grimm SA, Pulido JS, Jahnke K et al. Primary intraocular lymphoma: an IPCNSLCG Report. Ann Oncol 2007;18:1851–5.PubMedCrossRefGoogle Scholar
  220. 6.
    Nguyen PL, Chakravarti A, Finkelstein DM et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507–13PubMedGoogle Scholar
  221. 7.
    Omuro AM, DeAngelis LM, Yahalom J et al. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005;64:69–74PubMedGoogle Scholar
  222. 8.
    Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma. J Clin Oncol 2003;21:4483–8PubMedGoogle Scholar
  223. 9.
    Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006;24:3865–70PubMedGoogle Scholar
  224. 1.
primary-CNS-lymphoma/HealthProfessional NCI Cancer TopicsGoogle Scholar
  225. 2. E-medicineGoogle Scholar
  226. 3. Lymphoma Info PortalGoogle Scholar
  227. 4. Freiburg ProtocolGoogle Scholar
  228. 1.
    Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415–20PubMedGoogle Scholar
  229. 2.
    Cohen SM, Petryk M, Varma M et al. Non-Hodgkin’s Lymhoma of Mucosa-Associated Lymphoid Tissue. Oncolist 2006;11:1100–17Google Scholar
  230. 3.
    ESMO Guidelines Working Group. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii59–60Google Scholar
  231. 4.
    Farinha P, Gascoyne R. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncologist 2005;26:6370–8Google Scholar
  232. 5.
    Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changes over the past 10 years? Br J Haematol 2006;136:521–38PubMedGoogle Scholar
  233. 6.
    Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-53PubMedGoogle Scholar
  234. 7.
    Schmidt WP, Schmitz N, Sonnen R. Conservative management of gastric lymphoma: the treatment option of choice. Leuk Lymphoma 2004;45:1847–52PubMedGoogle Scholar
  235. 1. Intl Extranodal Lymphoma SGGoogle Scholar
  236. 2. Lymphoma Info NetworkGoogle Scholar
  237. 3. Lymphoma Info PortalGoogle Scholar
  238. 4. E-medicineGoogle Scholar
  239. 1.
    Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008;26:480–92PubMedGoogle Scholar
  240. 2.
    Bladé J. Monoclonal Gammopathy of undetermined significance. N Engl J Med 2006;355:2765–70PubMedGoogle Scholar
  241. 3.
    Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32PubMedGoogle Scholar
  242. 4.
    ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii44–6Google Scholar
  243. 5.
    Gonzalez D, van der Burg M, García-Sanz M et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112–21PubMedGoogle Scholar
  244. 6.
    Katzel JA, Hari P, Vesole DH. Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 2007;57:301–18PubMedGoogle Scholar
  245. 7.
    Kyle RA, Rajkumar SV. Multiple myeloma. Blod 2008;111:2962–72Google Scholar
  246. 8.
    Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20PubMedGoogle Scholar
  247. 9.
    Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008;140:365–77PubMedGoogle Scholar
  248. 1. Leukemia, University of BonnGoogle Scholar
  249. 2. Mult Myeloma Res FoundationGoogle Scholar
  250. 3. Medline PlusGoogle Scholar
  251. 4. Intl Myeloma FoundationGoogle Scholar
  252. 5. E-medicineGoogle Scholar
  253. 1.
    Chen CI. Treatment for Waldenström’s macroglobulinemia. Ann Oncol 2004;15:550–8PubMedGoogle Scholar
  254. 2.
    Dimopoulos MA, Kyle RA, Anagnostopoulos A et al. Diagnosis and management of Waldenström’s macroglobulinemia. J Clin Oncol 2005;23:1564–77PubMedGoogle Scholar
  255. 3.
    Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol 2007;138:700–20PubMedGoogle Scholar
  256. 4.
    Johnson SA, Birchall J, Luckie C et al. Guidelines on the management of Waldenström macroglobulinemia. Br J Haematol 2006;132:683–97PubMedGoogle Scholar
  257. 5.
    Kyle RA, Treon SP, Alexanian R et al. Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinemia. Semin Oncol 2003;30:116–20PubMedGoogle Scholar
  258. 6.
    Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Workshop on Waldenström’s macroglobulinemia. Blood 2006; 207:3442–6Google Scholar
  259. 1. Intl Waldenström FoundationGoogle Scholar
  260. 2. Medline PlusGoogle Scholar
  261. 3. E-medicineGoogle Scholar
  262. 1.
    Aricò M. Langerhans cell histiocytosis in adults: more questions than answers? Eur J Cancer 2004;40:1467–73PubMedGoogle Scholar
  263. 2.
    Gadner H, Grois N, Pötschger U et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008;111:2556–62PubMedGoogle Scholar
  264. 3.
    Geissmann F, Lepelletier Y, Fraitag S et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001;97:1241–8PubMedGoogle Scholar
  265. 4.
    Götz G, Fichter J. Langerhans cell histiocytosis in 58 adults. Eur J Med Res 2004;9:510–4PubMedGoogle Scholar
  266. 5.
    Steiner M, Matthes-Martin S, Attarbaschi A et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215–25PubMedGoogle Scholar
  267. 6.
    Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol 2006;76:363–8PubMedGoogle Scholar
  268. 7.
    Vassallo R, Ryu JH, Colby TV et al. Pulmonary Langerhans cell histiocytosis. N Engl J Med 2000;342:1969–78PubMedGoogle Scholar
  269. 1. Histiocytosis Assoc AmericaGoogle Scholar
  270. 2. Histiocyte SocietyGoogle Scholar
  271. 3. Medline PlusGoogle Scholar
  272. 4. E-medicineGoogle Scholar
  273. 1.
    Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004;55:419–32PubMedGoogle Scholar
  274. 2.
    Kirshenbaum AS, Goff JP, Semere T et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34+ ,c-kit+ , and expresses aminopeptidase N (CD13). Blood 1999;94:2333–42PubMedGoogle Scholar
  275. 3.
    Ma Y, Zeng S, Metcalfe DD et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors. Blood 1002;99:1741 4Google Scholar
  276. 4.
    Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001;25:577–82PubMedGoogle Scholar
  277. 5.
    Pardanani A, Ketterling RP, Brockman SR et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093–6PubMedGoogle Scholar
  278. 6.
    Tefferi A, Li CY, Butterfield JH et al. Treatment of systemic mast cell disease with cladribine. N Engl J Med 2001;344:307–9PubMedGoogle Scholar
  279. 7.
    Valent P, Akin C, Sperr WR et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005;46:35–48PubMedGoogle Scholar
  280. 8.
    Yavuz AS, Lipsky PE, Yavuz S et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661–5PubMedGoogle Scholar
  281. 1. Mastocytosis SocietyGoogle Scholar
  282. 2. Mastocytosis Fact SheetGoogle Scholar
  283. 3. E-medicineGoogle Scholar
  284. 4. Mastocytosis KidsGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • Ralph Waesch
    • 1
  • Werner Digel
    • 1
  • Michael Luebbert
    • 2
  • Kristina Heining-Mikesch
    • 2
  • Cornelius Waller
    • 3
  • W. Lange
  • Jürgen Heinz
    • 1
  • Jürgen Finke
    • 4
  • Jan Burger
    • 5
  • Gerald Illerhaus
    • 3
  • Reinhard Marks
    • 2
  • Alexandros Spyridonidis
    • 1
  • Claudia I. Müller
    • 1
  • Monika Engelhardt
    • 1
  • Marcus Stockschläder
    • 6
  1. 1.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  2. 2.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  3. 3.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  4. 4.Department of Hematology and OncologyUniversity Medical CenterFreiburgGermany
  5. 5.MD AndersonHoustonGermany
  6. 6.Institute of Hemostaseology and Transfusion MedicineDüsseldorf University HospitalDüsseldorfGermany

Personalised recommendations